Biopolitics for the 21st Century
By Marcy Darnovsky,
2020 Science
| 12. 14. 2009
Much appreciation is due to Andrew for his courage in soliciting "alternative perspectives" on technology innovation and life in the 21st century. I can't help but observe that his nervousness about doing so is one small sign that something is amiss in what he calls "the interface between emerging technologies and society."
One challenge we face in mending that interface is a tendency toward over-enthusiasm about prospective technologies. Another is the entanglement of technology innovation and commercial dynamics. Neither of these is brand new.
Back in the last century, the 1933 Chicago World's Fair took "technological innovation" as its theme and "A Century of Progress" as its formal name. Its official motto was "Science Finds, Industry Applies, Man Conforms."
The slogan shamelessly depicts "science" and "industry" as dictator - or at least drill sergeant - of humanity. It anoints industrial science as a rightful decision-maker about human ends, and an inevitable purveyor of societal uplift.
Today the 1933 World's Fair slogan seems altogether crass. But have we earned our cringe? We'd like to think that we're more realistic about science...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
